These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 16103104

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.
    Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG, Mixan BJ, Lee WP, Lin Z, Valdez P, Wahl AF, Grewal IS.
    Cancer Res; 2005 Sep 15; 65(18):8331-8. PubMed ID: 16166310
    [Abstract] [Full Text] [Related]

  • 5. Combined therapeutic effect of a monoclonal anti-idiotype tumor vaccine against NeuGc-containing gangliosides with chemotherapy in a breast carcinoma model.
    Fuentes D, Avellanet J, Garcia A, Iglesias N, Gabri MR, Alonso DF, Vazquez AM, Perez R, Montero E.
    Breast Cancer Res Treat; 2010 Apr 15; 120(2):379-89. PubMed ID: 19377876
    [Abstract] [Full Text] [Related]

  • 6. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells.
    Salem ML, Kadima AN, El-Naggar SA, Rubinstein MP, Chen Y, Gillanders WE, Cole DJ.
    J Immunother; 2007 Jan 15; 30(1):40-53. PubMed ID: 17198082
    [Abstract] [Full Text] [Related]

  • 7. CD40 monoclonal antibody activation of antigen-presenting cells improves therapeutic efficacy of tumor-specific T cells.
    Bergstrom RT, Silverman DA, Chambers K, Kim JA.
    Otolaryngol Head Neck Surg; 2004 Jan 15; 130(1):94-103. PubMed ID: 14726917
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
    Proietti E, Greco G, Garrone B, Baccarini S, Mauri C, Venditti M, Carlei D, Belardelli F.
    J Clin Invest; 1998 Jan 15; 101(2):429-41. PubMed ID: 9435316
    [Abstract] [Full Text] [Related]

  • 14. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies.
    Khubchandani S, Czuczman MS, Hernandez-Ilizaliturri FJ.
    Curr Opin Investig Drugs; 2009 Jun 15; 10(6):579-87. PubMed ID: 19513947
    [Abstract] [Full Text] [Related]

  • 15. CD40 plays an essential role in the activation of human B cells by murine EL4B5 cells.
    Kwekkeboom J, De Boer M, Tager JM, De Groot C.
    Immunology; 1993 Jul 15; 79(3):439-44. PubMed ID: 7691726
    [Abstract] [Full Text] [Related]

  • 16. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
    Li J, Davis J, Bracht M, Carton J, Armstrong J, Gao W, Scallon B, Fung R, Emmell E, Zimmerman M, Griswold DE, Li L.
    Int Immunopharmacol; 2006 Jun 15; 6(6):880-91. PubMed ID: 16644473
    [Abstract] [Full Text] [Related]

  • 17. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody.
    Fransen MF, Sluijter M, Morreau H, Arens R, Melief CJ.
    Clin Cancer Res; 2011 Apr 15; 17(8):2270-80. PubMed ID: 21389097
    [Abstract] [Full Text] [Related]

  • 18. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
    Li B, Lin J, Vanroey M, Jure-Kunkel M, Jooss K.
    Clin Immunol; 2007 Oct 15; 125(1):76-87. PubMed ID: 17706463
    [Abstract] [Full Text] [Related]

  • 19. Functional and in situ evidence for nitric oxide production driven by CD40-CD40L interactions in graft-versus-leukemia reactivity.
    Müerköster S, Laman JD, Rocha M, Umansky V, Schirrmacher V.
    Clin Cancer Res; 2000 May 15; 6(5):1988-96. PubMed ID: 10815924
    [Abstract] [Full Text] [Related]

  • 20. A monoclonal antibody reactive with a 40-kDa molecule on fetal thymocytes and tumor cells blocks proliferation and stimulates aggregation and apoptosis.
    Fernandes DM, Baird AM, Berg LJ, Rock KL.
    J Immunol; 1999 Aug 01; 163(3):1306-14. PubMed ID: 10415028
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.